175 related articles for article (PubMed ID: 3286129)
1. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia.
Bes A; Eyssette M; Pierrot-Deseilligny E; Rohmer F; Warter JM
Curr Med Res Opin; 1988; 10(10):709-18. PubMed ID: 3286129
[TBL] [Abstract][Full Text] [Related]
2. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
3. Comparative profile of tizanidine in the management of spasticity.
Lataste X; Emre M; Davis C; Groves L
Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
[TBL] [Abstract][Full Text] [Related]
4. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
Medici M; Pebet M; Ciblis D
Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
[TBL] [Abstract][Full Text] [Related]
6. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
9. Treatment of spasticity with tizanidine in multiple sclerosis.
Lapierre Y; Bouchard S; Tansey C; Gendron D; Barkas WJ; Francis GS
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):513-7. PubMed ID: 3676923
[TBL] [Abstract][Full Text] [Related]
10. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Wagstaff AJ; Bryson HM
Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
[TBL] [Abstract][Full Text] [Related]
11. [Tizanidine as treatment of spasticity in patients with hemiplegia caused by a CVA or brain injury].
Weynants L; Van Laere M
Acta Belg Med Phys; 1990; 13(1):19-22. PubMed ID: 2336897
[No Abstract] [Full Text] [Related]
12. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
Ogawa N; Asanuma M; Hirata H; Ota Z; Yamawaki Y; Yamamoto M
J Int Med Res; 1992 Feb; 20(1):78-86. PubMed ID: 1568522
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
14. Summary of combined clinical analysis of controlled clinical trials with tizanidine.
Wallace JD
Neurology; 1994 Nov; 44(11 Suppl 9):S60-8; discussion S68-9. PubMed ID: 7970013
[TBL] [Abstract][Full Text] [Related]
15. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
Gelber DA; Good DC; Dromerick A; Sergay S; Richardson M
Stroke; 2001 Aug; 32(8):1841-6. PubMed ID: 11486114
[TBL] [Abstract][Full Text] [Related]
16. Tizanidine in the treatment of spasticity.
Newman PM; Nogues M; Newman PK; Weightman D; Hudgson P
Eur J Clin Pharmacol; 1982; 23(1):31-5. PubMed ID: 6751834
[TBL] [Abstract][Full Text] [Related]
17. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
[TBL] [Abstract][Full Text] [Related]
18. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin.
Hennies OL
J Int Med Res; 1981; 9(1):62-8. PubMed ID: 6451461
[TBL] [Abstract][Full Text] [Related]
19. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
[TBL] [Abstract][Full Text] [Related]
20. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
Stien R; Nordal HJ; Oftedal SI; Slettebø M
Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
